Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 455 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Solution Vehicle Clear all
Completed Phase 2 Interventional Results available

Nesvategrast (OTT166) in Diabetic Retinopathy (DR)

NCT05409235
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
OTT166, Vehicle control
Drug
Lead sponsor
OcuTerra Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
67
States / cities
Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.

NCT03131154
View directory record Official record
Conditions
Non-infectious Anterior Uveitis
Interventions
ADX-102 Ophthalmic Solution (0.5%), Vehicle of ADX-102 Ophthalmic Solution
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
27
States / cities
Birmingham, Alabama • Phoenix, Arizona • Prescott, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Early Phase 1 Interventional

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

NCT04792580
View directory record Official record
Conditions
Graft-versus-host-disease, Ocular Graft-versus-host Disease
Interventions
Lifitegrast 5% Ophthalmic Solution, Placebo
Drug
Lead sponsor
Richard W Yee, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion

NCT02061813
View directory record Official record
Conditions
Head Lice
Interventions
Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate, Saline 0.9%, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Oct 22, 2026, 11:15 PM EDT
Terminated Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Bimatoprost Ophthalmic Solution in Paediatric Patients With Glaucoma

NCT01426113
View directory record Official record
Conditions
Glaucoma
Interventions
bimatoprost ophthalmic solution formulation A, timolol ophthalmic solution, bimatoprost vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
2 Months to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 22, 2026, 11:15 PM EDT
Recruiting Phase 2 Interventional

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

NCT07503886
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
DFL24498, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Chandler, Arizona • Azusa, California • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction

NCT00226759
View directory record Official record
Conditions
Knee Injuries
Interventions
OMS103HP, Vehicle
Drug
Lead sponsor
Omeros Corporation
Industry
Eligibility
15 Years to 65 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
18
States / cities
Encinitas, California • Redwood City, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2012 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye

NCT03019627
View directory record Official record
Conditions
Dry Eye
Interventions
NGF, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 8, 2019 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 4 Interventional Results available

Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers

NCT05505292
View directory record Official record
Conditions
Dry Eye
Interventions
Lifitegrast 5% Ophthalmic Solution, Lifitegrast Ophthalmic Solution Vehicle
Drug · Other
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

NCT00423007
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bromfenac, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Early Phase 1 Interventional

Respiratory Strength Training in Persons With Amyotrophic Lateral Sclerosis (ALS)

NCT02710110
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
PowerLung trainer, Micro Mouth Pressure Meter, Pulmonary Function Testing, Videofluoroscopic swallowing study, Swallowing Quality of Life Questionnaire, Iowa Oral Pressure Instrument, Capsaicin
Device · Procedure · Other + 1 more
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Rhopressa for Corneal Edema Associated With Fuchs Dystrophy

NCT04051463
View directory record Official record
Conditions
Fuchs Endothelial Dystrophy
Interventions
Netarsudil Ophthalmic Solution, Placebo
Drug
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis

NCT02667275
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101 Solution, Vehicle Solution
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced Oct 22, 2026, 11:15 PM EDT
Not listed Phase 3 Interventional

Study of EBI-005 in Dry Eye Disease (DED)

NCT02405039
View directory record Official record
Conditions
Dry Eye
Interventions
EBI-005, Placebo
Drug
Lead sponsor
Eleven Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
Birmingham, Alabama • Newport Beach, California • Hamden, Connecticut + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2015 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of AR-15512

NCT05285644
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Glendale, California • Torrance, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Effect of AB-101 in Breast Cancer Survivors

NCT03592121
View directory record Official record
Conditions
Sexual Dysfunction, Sexual Arousal Disorder, Sexual Dysfunction, Physiological, Breast Cancer, Nipple Disorder, Neuropathy, Cancer of Breast
Interventions
AB-101, Placebo
Drug
Lead sponsor
Applied Biology, Inc.
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate AXR-159 Ophthalmic Solution in Patients With Dry Eye Disease

NCT03598699
View directory record Official record
Conditions
Dry Eye
Interventions
AXR-159, Vehicle
Drug
Lead sponsor
AxeroVision, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Andover, Massachusetts • Raynham, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of a Eye Drop for Eye Allergy

NCT00889330
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
alcaftadine, Placebo
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
2
States / cities
Fairfield, Ohio • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 6, 2015 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety of USB005 in Healthy Volunteers

NCT03615196
View directory record Official record
Conditions
Healthy Volunteers
Interventions
USB005 (aclerastide) Ophthalmic Solution, USB005 Ophthalmic Solution Placebo
Drug
Lead sponsor
US Biotest, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

Study of A-101 for the Treatment of Seborrheic Keratosis

NCT02260180
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Portland, Oregon • Fort Washington, Pennsylvania • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca

NCT02688556
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
cyclosporine, vehicle of OTX-101
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
745 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
3
States / cities
Rancho Cordova, California • Edgewood, Kentucky • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Results available

Safety Study of Tivanisiran to Treat Dry Eye

NCT05310422
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Tivanisiran sodium ophthalmic solution, Vehicle ophthalmic solution
Drug
Lead sponsor
Sylentis, S.A.
Industry
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Chandler, Arizona • Phoenix, Arizona • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety & Efficacy of Pilocarpine Eye Solutions for Temporary Improvement of Near Vision in Presbyopic Adults

NCT04657172
View directory record Official record
Conditions
Presbyopia
Interventions
Pilocarpine Ophthalmic, Placebo
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
40 Years to 60 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
9
States / cities
Azusa, California • Newport Beach, California • Fort Collins, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Oct 22, 2026, 11:15 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

NCT01863953
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
Fixed-Combination Bimatoprost/Brimonidine, Bimatoprost Ophthalmic Solution 0.01%, Vehicle Ophthalmic Solution, Brimonidine Tartrate Ophthalmic Solution 0.2%
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 22, 2026, 11:15 PM EDT